Loading...
Market
What will be Wegovy's market share in the global obesity treatment sector by end of 2024?
4
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Market research reports or Novo Nordisk's financial statements
Story
Novo Nordisk's Wegovy Shows Sustained 10% Weight Loss, Heart Protection Over Four Years
May 14, 2024, 12:21 PM
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, according to the company. The longest study of the obesity drug Wegovy has shown people maintain significant weight loss for at least four years, with fewer serious adverse events than those given a placebo 'dummy' treatment. This sustained weight loss potentially boosts the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug. A new analysis shows that the drug also provides heart protection.
View original story
Similar markets
<20% • 25%
20%-40% • 25%
40%-60% • 25%
>60% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
<$5 billion • 25%
$5 billion to $10 billion • 25%
$10 billion to $15 billion • 25%
>$15 billion • 25%
Yes • 50%
No • 50%
Novo Nordisk launches competitive drug • 30%
Pfizer accelerates similar drug development • 30%
No significant competitor response • 40%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Ozempic >50% • 25%
Ozempic 25-50% • 25%
Ozempic <25% • 25%
Other brands dominate • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%